Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Don't put other nasty ingredients into your body
Weight-loss drug forecasts jump to $150 billion as supply grows, Reuters, May 28, 2024
Genetic predisposition does not predict exact medication response or guarantee outcomes
Key Takeaways: Read also: Oil Sinks ~5%, Dow Jumps 600+ as Trump Halts Iran Strike Pfizer keeps expanding its GLP-1 portfolio in China through its second licensing deal in just a few months Ecnoglutide is a once-weekly injection already approved in China, with a weight management application currently under review Competition in the GLP-1 space is heating up fast, with heavyweights like Novo Nordisk and Eli Lilly already leading the pack Ecnoglutide belongs to a class of drugs known as GLP-1 receptor agonists, the same category as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro
